Skip to NavigationSkip to content


The global rise in antibiotic resistance threatens infection prevention and cure

Published on 20/05/19 at 01:23pm

Dr Bill Love, Founder and Chief Scientific Officer of Destiny Pharma, discusses the rise of antimicrobial resistance (AMR), the antibiotic stewardship required to offset this global threat, and the additional incentivisation initiatives needed to promote innovation, as well as the role of preventative antimicrobial treatments as an important element of this global fight against AMR.

A day in the life: Lance Hill, CEO at Within3

Published on 17/05/19 at 09:23am

Could you give a short history of how you came to be in your current role?

I've spent my entire career in technology.  My passion is how technology is applied to change the way we work and live.  When social media technologies emerged, I became very interested in how this new technology paradigm would change the workplace.  That led to Within3, where we focus on improving communication throughout all the stakeholder groups within healthcare. 

Insider Interview: Paving paths in prostate cancer

Published on 16/05/19 at 11:39am

Joaquin Casariego Garcia Luben, Medical Affairs Director Europe, Middle East & Africa, Prostate Cancer for Johnson & Johnson (pictured) discusses Janssen’s vision in Oncology and how the company is building on its heritage in prostate cancer to deliver transformational outcomes for patient.

What is Janssen’s vision in oncology?

Will mobile phones save the NHS?

Published on 07/05/19 at 11:38am

The NHS is sick. According to politicians and NHS chiefs, the cure involves a strong dose of mHealth. Louis Goss asks to what extent mobile health apps can solve the problems of the increasingly strained health service.

Understaffed, underfunded and overstretched; Britain’s beloved National Health Service is under pressure like never before. As said succinctly in a parliamentary report from 2017: “Our NHS, our ‘national religion’, is in crisis and the adult social care system is on the brink of collapse.”

The price of access: Can the NHS afford Orkambi?

Published on 29/04/19 at 11:43am

The impasse over access to Vertex’s Orkambi for cystic fibrosis patients in England and Wales has revealed the cracks in the NHS’ regulatory system. Matt Fellows explores where the core issues lie in the debate, and what can be done to prevent future breakdowns in communication for the good of patients.

Working Life: Dr Todd Hobbs, Vice President and Chief Medical Officer, Novo Nordisk

Published on 24/04/19 at 11:29am

Novo Nordisk's VP and CMO discusses his leap from family medicine into the pharma industry, his biggest achievements, and how having diabetes himself has shaped his outlook on treatment throughout his career.

You are a trained medical doctor; how did that shape your early career?

Medical cannabis: A green light for patients in need?

Published on 15/04/19 at 10:00am

Spinnaker Opportunities announced in February it had reached a preliminary agreement to acquire cannabis oil-focused research firm Kanabo Research and its growing portfolio of activities. Spinnaker Chairman Andy Morrison explains the move towards medical cannabis, and the opportunities and challenges ahead for healthcare as attitudes towards the drug slowly shift.

Can you provide a bit of background on Spinnaker?

Living with a rare chromosome disorder

Published on 11/04/19 at 12:28pm

Rebecca Pender’s daughter Hannah lives with the ultra-rare condition Inv Dup Del 8p, a genetic arrangement that affects just 80 people worldwide. She recounts the struggle to secure a diagnosis, and how the experience shaped her attitude on how we confront rare disease.

Can you shed some light on the nature of Inv Dup Del 8p?

Protecting public health: Is real-world evidence the key?

Published on 08/04/19 at 01:49pm

In often tough regulatory climates and with threats to public health are growing in sceptical corners of society, the need to deliver treatments and preventative therapies is a key concern for industry and national healthcare bodies. Matt Fellows explores how incorporating wider use of real-world evidence into these systems could be the solution we need.

How I learned to stop worrying and love the placebo effect

Published on 01/04/19 at 11:44am

Louis Goss talks to Harvard Medical School placebo expert Dr Ted Kaptchuk in asking what the placebo effect means for doctors, patients and pharmaceutical companies in clinical trials.

On 14 February 2019, Danish firm Lundbeck and its Japanese partner Otsuka announced the results of two Phase 3 trials looking into the effectiveness of their previously successful antipsychotic, Rexulti (brexpiprazole), as a treatment for manic episodes associated with bipolar I disorder.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches